No Data
Clarus Keeps Their Buy Rating on Data Commun Management (DCM)
Clarus Sets Fourth Quarter and Full Year 2024 Conference Call for Thursday, March 6, 2025, at 5:00 P.m. ET
Clarus Corporation's (NASDAQ:CLAR) Intrinsic Value Is Potentially 93% Above Its Share Price
Testosterone Replacement Therapy Market Forecast Report 2025-2033, With Key Player Profiles for AbbVie, Clarus Therapeutics, Ferring Pharmaceuticals, Lupin, Pfizer, Teva Pharmaceuticals and More
Express News | Clarus- Co,Bdel Received Grand Jury Subpoenas for Documents Relating to, Among Other Things, Certain Avalanche Transmitters Distributed by Bdel
Does Clarus Corp (CLAR) Have Significant Growth Potential?
Press Release: Roger Werner Appointed to Clarus' Board of Directors
